Latest From AngioSoma Inc.
Market Intel: Pain Is Biggest Market For Transdermal Drug Delivery But Not A Patch Over Neuro For Growth
The growing aging population and rising obesity rates are paving the way for patch-based drug delivery systems to treat such common age-related diseases as Alzheimer's and Parkinson's, hormonal deficiencies, heart disease, as well as for managing acute and chronic pain patients. According to a new report by Meddevicetracker, the global market for transdermal patch products will reach $8.1bn by 2021, a CAGR of 2.9% from 2016. In this feature, we'll take a closer look at the overall market and the key players in the individual segments in this overall market. We'll take a deep dive into the neurological disorders segment, which is expected to see the biggest growth in the overall segment. We'll also feature physician specialty surveys outlining the pros and cons of using patch-based systems.
A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.
Mannatech founder Robbins leaves board; Nutra recalls GNC Women's supplement; historic UK center licenses Agragen omega-3 technology; and AngioSoma gains nutraceutical formulation patents
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2016.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- AngioSoma Inc.
- Senior Management
Ken Stephenson, CEO
Alexanderia Blankenship, EVP, COO
- Contact Info
Phone: (832) 781-8521
14001 Walden Rd., Ste. 600
Montgomery, TX 77356
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.